Medicare Expenditures of Atezolizumab for a Withdrawn Accelerated Approved Indication-Reference-Cited by-同舟云学术

Medicare Expenditures of Atezolizumab for a Withdrawn Accelerated Approved Indication

Published:2021-11-01 Issue:11 Volume:7 Page:1720
ISSN:2374-2437
Container-title:JAMA Oncology
language:en
Short-container-title:JAMA Oncol

Author:

Ballreich Jeromie¹²,Bennet Charles³⁴,Moore Thomas J.²⁵,Alexander G. Caleb¹²⁶⁷

Affiliation:

1. Department of Health Policy & Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland

2. Center for Drug Safety and Effectiveness, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland

3. The University of South Carolina College of Pharmacy, Columbia

4. The Center for Comparative Effectiveness, The City of Hope Comprehensive Cancer Center, Duarte, California

5. Department of Epidemiology, Milken Institute School of Public Health, George Washington University, Washington, DC

6. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland

7. Division of General Internal Medicine, Johns Hopkins Medicine, Baltimore, Maryland

Publisher

American Medical Association (AMA)

Subject

Oncology,Cancer Research

Link

https://jamanetwork.com/journals/jamaoncology/articlepdf/2784217/jamaoncology_ballreich_2021_ld_210017_1636656394.94898.pdf

Reference6 articles.

1. Assessment of the clinical benefit of cancer drugs receiving accelerated approval.;Gyawali;JAMA Intern Med,2019

2. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial.;Powles;Lancet,2018

3. US Food and Drug Administration. CFR—Code of Federal Regulations Title 21. Accessed March 16, 2021. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=1.4

4. US Food and Drug Administration. FDA Oncologic Drugs Advisory Committee to review status of six indications granted accelerated approval. Accessed March 16, 2021. https://www.fda.gov/news-events/fda-brief/fda-brief-fda-oncologic-drugs-advisory-committee-review-status-six-indications-granted-accelerated

5. US Food and Drug Administration. Authors’ analysis of the FDA's CDER Accelerated Approvals database. Accessed June 16, 2021. https://www.fda.gov/drugs/nda-and-bla-approvals/accelerated-approvals

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Special FDA designations for drug development: orphan, fast track, accelerated approval, priority review, and breakthrough therapy;The European Journal of Health Economics;2023-11-14

2. US Food and Drug Administration Accelerated Approval Program for Nononcology Drug Indications Between 1992 and 2018;JAMA Network Open;2022-09-09

3. Medicare Spending on Drugs With Accelerated Approval;Annals of Internal Medicine;2022-07

4. Spending by the Centers for Medicare & Medicaid Services Before and After Confirmation of Benefit for Drugs Granted US Food and Drug Administration Accelerated Approval, 2012 to 2017;JAMA Health Forum;2022-05-27